The authors have designed high-throughput screens to identify compounds that promote or inhibit terminal differentiation of primary human epidermal keratinocytes. Eleven known inhibitors of signaling pathways and approximately 4000 compounds of diverse structure were screened using an In-Cell Western system based on immunofluorescent staining of the terminal differentiation marker, involucrin. Staurosporine, a nonspecific protein kinase C inhibitor, and H89, a protein kinase A inhibitor, promoted expression of involucrin. Conversely, U0126, a MEK inhibitor, and SAHA or SBHA, 2 histone deacetylase inhibitors, reduced the expression of involucrin during calcium-induced stratification. In addition, the authors found 1 novel compound that induced keratinocyte differentiation and 2 novel compounds that were inhibitory to calcium-induced differentiation. The differentiation-inducing compound also inhibited growth of a human squamous cell carcinoma line by stimulating both differentiation and apoptosis. Because the compound affected the tumor cells at a lower concentration than primary keratinocytes, it may have potential as an antitumor therapy. (Journal of Biomolecular Screening 2006:977-984) 
INTRODUCTION
M AMMALIAN INTERFOLLICULAR EPIDERMIS is a multilayered tissue in which proliferation takes place in the basal layer of cells attached to the underlying basement membrane. 1 Cells undergo terminal differentiation as they move through the suprabasal layers to the surface of the skin. The culmination of the differentiation process is assembly of the cornified envelope, consisting of transglutaminase cross-linked proteins and lipids, which forms a robust barrier against insults from the environment. 1 Prior to envelope assembly, in the lower suprabasal layers, a large number of protein markers of terminal differentiation are expressed, including the cornified envelope precursor involucrin. 2 Epidermal cells, known as keratinocytes, can be grown in culture and can reconstitute an epidermis that is used clinically for grafting burn victims. 3 Markers of terminal differentiation, such as involucrin, are expressed in culture, and analysis of the factors that control their expression has provided valuable information about the properties of normal and diseased epidermis. In addition, many cell lines derived from human squamous cell carcinomas (SCCs) have been generated and used to study the mechanisms underlying the reduced differentiation potential of malignant keratinocytes. 4, 5 Compounds that promote terminal differentiation of keratinocytes could potentially be used as treatments for both benign skin diseases, such as psoriasis, and SCCs.
Recently, high-throughput screening (HTS) techniques 6 have provided effective methods to search for molecules that modulate specific molecular pathways or that affect a type of cell behavior, such as proliferation or invasion. 7 A number of phenotypic screens, based on immunodetection of proteins or posttranslationally modified proteins in fixed cells, have been described previously. [8] [9] [10] [11] In this report, we employed the In-Cell Western system, which enabled us to identify the expression of 2 proteins simultaneously using an immunofluorescent staining method. To date, there have been only a few reports of applying high-throughput screens to identify compounds that promote keratinocyte differentiation. 12, 13 We describe the development and validation of such assays and report a novel compound that modifies the differentiation of epidermal keratinocytes and induces differentiation and apoptosis of SCC cells.
MATERIALS AND METHODS

Cell culture
Stocks of primary human keratinocytes were prepared from neonatal human foreskin and cultured in the presence of a mitomycin C-treated J2-3T3 feeder layer, as described previously. 14 The culture medium consisted of 1 part Ham's F12 medium and 3 parts DMEM with 1.8 × 10 -4 M adenine (FAD), supplemented with 10% fetal calf serum (FCS), 0.5 µg/ml hydrocortisone, 5 µg/ml insulin, 10 -10 M cholera toxin, and 10 ng/ml epidermal growth factor (HICE). The same conditions were used to grow stocks of SCC4, a poorly differentiated cell line derived from a human tongue squamous cell carcinoma. 15 For compound screening, primary keratinocytes and SCC4 were cultured in keratinocyte serum-free medium (KSFM; Invitrogen, Carlsbad, CA) without feeders. A total of 2 × 10 3 cells were seeded in clear, polystyrene, flat-bottomed, 384-well plates (Corning Inc., Acton, MA) in KSFM containing 0.05 mM calcium chloride (CaCl 2 ) 2 days before addition of compounds.
Chemicals and antibodies
The following known compounds were tested: LY294002 (Calbiochem, Merck Biosciences, Nottingham, UK), a nonspecific PI3 kinase inhibitor; staurosporine (Sigma-Aldrich, St. Louis, MO), H89 (Sigma), and H9 (Calbiochem), protein kinase inhibitors; PD98059 (Calbiochem) and U0126 (Calbiochem), MEK inhibitors; a Rho kinase (ROCK) inhibitor, Y-27632 (Calbiochem); and MS-275 (Calbiochem), SAHA (BioCat GmbH, Germany), and SBHA (BioCat), histone deacetylase (HDAC) inhibitors. Geldanamycin (Calbiochem) and the pyrazole CCT018159, 16 which inhibit the ATPase activity of the molecular chaperone HSP90, were also used. In addition, we screened 1990 compounds from the National Cancer Institute Developmental Therapeutics Program Diversity Set (http://dtp.nci.nih.gov/branches/ dscb/diversity_explanation.html) and a further 2000 chemically diverse compounds from a collection in the Cancer Research UK Centre for Cancer Therapeutics. SY5, 17 BC-1, 18 mouse monoclonal anti-β-tubulin antibody, and rabbit polyclonal anti-actin antibody (all from Sigma) were used for detection of involucrin, transglutaminase-I, β-tubulin, and actin, respectively.
Addition of compounds to cells in microplates
Compounds, dissolved in DMSO, were administered to each well at a nominal concentration of 10 to 20 µM. The same volume (5 µl) of DMSO was added to control wells (0.2% final concentration); this concentration of DMSO did not affect viability, proliferation, or differentiation. For the screen to identify differentiation-inhibiting molecules, the addition of compounds was followed, 30 min later, by the addition of 1.0 mM CaCl 2 to the culture medium. Cells were assayed 48 h after administration of compounds.
HTS assay using the In-Cell Western system
The In-Cell Western system is an immunocytochemical assay performed in microplate format, in which target-specific primary antibodies and labeled secondary antibodies are used to quantify target proteins in fixed cells (LI-COR Biosciences, Lincoln, NE). Plates of 384 wells with keratinocytes were fixed with 4% formaldehyde in phosphate-buffered saline (PBS) for 20 min, washed 4 times with 0.1% Triton X-100 in PBS, and blocked with Odyssey ® blocking buffer (LI-COR Biosciences). The cells were labeled with mouse monoclonal anti-involucrin antibody, SY5 (10 µg/ml) and rabbit polyclonal anti-actin antibody (1:200; Sigma), followed by Alexa Fluor ® 800-conjugated goat antimouse IgG and Alexa Fluor ® 680-conjugated goat antirabbit IgG (Invitrogen, Carlsbad, CA). The plates were washed manually 4 times with 0.1% Tween-20 in PBS after incubation with each antibody.
Staining was quantified using the Odyssey ® Infrared Imaging System (LI-COR Biosciences). The intensity ratio of involucrin to actin labeling was calculated, using actin to control for variation in cell number between wells. If the actin staining was very low for a compound in the primary screen, this was taken as an indication of potential cell toxicity, and the compound was excluded from the secondary screen.
The Z′ factor 19 was determined using data from samples treated with DMSO and 1.4 mM CaCl 2 (6 wells per plate) versus samples treated with DMSO in 0.05 mM CaCl 2 (26 wells per plate). In the primary screen, a single well containing each compound was tested. Each hit compound from the primary screens was retested in a secondary screen in 6 replicate wells.
Western blotting
Cells were washed twice with ice-cold PBS and lysed in ice-cold RIPA buffer (150 mM NaCl 2 , 50 mM Tris [pH 7.5], 1% Triton X-100, 1% sodium deoxycholate, 0.5 mM EDTA, and 0.1 mM EGTA) containing a protease inhibitor cocktail (Hoffman-La Roche Inc., Nutley, NJ). Protein concentrations were determined with the BCA protein assay kit (Perbio Science UK Ltd., Cramlington, UK). Five to 20 µg of proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis using an 8% polyacrylamide gel at 100 V and transferred to Hybond-P nitrocellulose membranes (GE Healthcare UK Ltd., Chalfont St. Giles, UK) using semidry blotting at 10 V for an hour. Blotted membranes were blocked with PBS containing 0.1% Tween-20 and 5% skim milk, then incubated with SY5 (0.1 µg/ml) or anti-β-tubulin antibody (1:50,000) overnight at 4°C. Proteins were visualized with antimouse or antirabbit IgG horseradish-peroxidase-linked antibodies (1:5000; GE Bioscience) for 1 h, followed by electrogenerated chemiluminescence detection (GE Bioscience).
Flow cytometry
For antibody labeling, primary human keratinocytes and SCC4 cells were harvested with trypsin/EDTA, fixed with 4% formaldehyde in PBS for 10 min, and permeabilized with 0.3% saponin in PBS for 10 min. The cells were labeled with antiinvolucrin monoclonal antibody, SY5 (10 µg/ml), or antitransglutaminase I monoclonal antibody, BC-1 (10 µg/ml), for 30 min followed by Alexa 488 conjugated goat antimouse antibody. Cells were analyzed using a FACScalibur II sorter and the Cell Quest FACS analysis system. For analysis of DNA content, cells were fixed in 70% ethanol, treated with 50 µg/ml RNase, stained with propidium iodide, and analyzed with the same system.
Luciferase assay
A 3.7-kb fragment of the human involucrin promoter that has been used to generate transgenic mice 20 was subcloned into pGL3 basic vector (Promega UK, Southampton, UK). The vector was transfected into primary human keratinocytes together with a control Renilla luciferase vector using Lipofectamine 2000 reagent (Invitrogen Ltd., Paisley, UK). Luciferase activities were measured using the dual luciferase reporter assay system (Promega) and a 96-well-formatted luminometer.
Clonogenicity assay
Keratinocytes (10 3 ) were plated per well of flat-bottomed, 24-well plates containing mitomycin C-treated J2-3T3 cells and cultured in FAD + FCS + HICE medium 14 for 10 days in the presence of a range of concentrations of each test compound. After 10 days, cells were fixed with 4% formaldehyde and stained with 1% Nile blue and 1% Crystal red. Colonyforming efficiency was calculated as the percentage of plated cells that formed colonies. All of the samples were analyzed in quadruplicate.
Cell proliferation assay
Keratinocytes (500 or 10 3 ) were seeded per well of flatbottomed, 24-well plates and cultured in KSFM (Invitrogen) in the presence or absence of one of the hit compounds, CCT002080 (20 µM), and cell number was determined at daily intervals. To analyze SCC4 and J2-3T3 cell proliferation, 96well plates were used. The number of cells per well was determined using a CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) in a 96-well plate reader. All of the samples were measured in triplicate.
RESULTS
Induction of involucrin expression by calcium switch detected using the In-Cell Western system
It has previously been shown that when primary keratinocytes are cultured in medium containing a low concentration of calcium ions, desmosome assembly is inhibited and the cells fail to stratify, with differentiated cells detaching into the culture medium. On addition of calcium ions, desmosome assembly occurs, and differentiated cells stratify and accumulate in the suprabasal layers. 21, 22 To verify the sensitivity and selectivity of the In-Cell Western system to screen for differentiationmodifying compounds, we analyzed the accumulation of involucrin-positive cells following an increase in the calcium concentration of the medium from 0.05 mM to 1.4 mM. Cells were also labeled with anti-actin antibodies to control for variation in cell number between wells.
Analysis of involucrin expression using the In-Cell Western system showed a reproducible increase following addition of CaCl 2 (Fig. 1A) . The results were consistent with the increase in luciferase activity of cells transfected with a luciferase reporter driven by the 3.7-kb involucrin promoter 20 (Fig. 1B) . Induction of involucrin was increased 2-to 3-fold in each assay. Because nonspecific staining was quite low when the primary antibody was substituted with IgG ( Fig. 1A) , the specificity of the SY5 antibody was considered sufficient for efficient detection of involucrin expression. The Z′ factor 19 of these control experiments was 0.40 to 0.56, a value considered acceptable for HTS. 7 
Screening inhibitors of known specificity
We next screened 11 known inhibitors of signaling pathways for their ability to induce involucrin as a marker of differentiation. Keratinocytes were treated with different concentrations of inhibitors in low-calcium medium ( Fig. 2A) . Although staurosporine, a nonspecific inhibitor of protein kinases, was cytotoxic at 10 µM, it stimulated expression of involucrin 2-fold when applied at the nontoxic concentration of 1 µM, with the involucrin/actin ratio tending to be higher than that seen with the positive control (1.4 mM CaCl 2 ). None of the other compounds had such a pronounced effect, although increased expression of involucrin was also observed in the presence of 10 µM H89 (protein kinase A inhibitor), PD98059 and U0126 (MEK inhibitors), the HSP90 ATPase inhibitors geldanamycin and CCT018159, and the ROCK inhibitor Y27632 ( Fig. 2A) .
The effect of staurosporine was confirmed by Western blotting using β-tubulin as a loading control: The level of involucrin protein was increased in keratinocytes that had been treated with the compound (Fig. 2B) . In addition, staurosporine treatment resulted in an increase in involucrin promoter activity that was similar to the increase observed when cells were treated with 1.0 mM CaCl 2 (Fig. 2C) . These results are in good agreement with earlier reports that staurosporine stimulates keratinocyte terminal differentiation. 23, 24 We next investigated whether any of the panel of compounds could block calcium-induced involucrin expression ( Fig. 3A) . Staurosporine at 1 µM had no effect on induction of involucrin expression ( Fig. 3A) . Staurosporine inhibited involucrin induction at 10 µM; however, this was associated with cell toxicity, as described above. Indeed, staurosporine concentrations as low as 0.1 µM induced some keratinocytes to undergo apoptosis, as evidenced by their sub-G1 DNA content 5 (M1 in Fig. 3B) .
Treatment of keratinocytes with U0126, a MEK-specific inhibitor, and SAHA, an HDAC inhibitor, decreased expression of involucrin by 10% to 20% compared to CaCl 2 addition alone (Fig. 3A) . MS-275, another HDAC inhibitor, was less effective. U0126 and the HDAC inhibitor SBHA inhibited the activity of the involucrin promoter by up to 70% as determined by the luciferase assay (Fig. 3C) . The ROCK inhibitor Y27632 caused increased expression of involucrin when assayed by In-Cell Western at 10 µM ( Fig. 2A; Fig. 3A ) but caused decreased involucrin promoter activity at 20 µM (Fig. 3C) , possibly reflecting cell toxicity at high concentrations. The inhibition of involucrin expression by U0126 is in good agreement with an earlier report. 25 We conclude that In-Cell Western is a valid method for large-scale screening of molecules that either promote or inhibit terminal differentiation of primary human keratinocytes.
Screening for novel differentiation-inhibiting compounds
To screen for novel compounds that inhibited terminal differentiation, keratinocytes in KSFM were transferred to 1.0 mM CaCl 2 in the presence or absence of each test compound. Using the In-Cell Western system, we identified 4 compounds ( Fig. 4) that inhibited the induction of involucrin expression following the calcium switch (Fig. 4A) . We screened each compound for its effect on the clonal growth of keratinocytes. Two of the compounds, CCT001909 (NCI 207895) and CCT070778, completely inhibited clonal growth when applied at 20 µM, suggesting that the reason for the inhibition of involucrin expression was that they were cytotoxic (Fig. 4B) . At low concentrations, the nitrobenzofuroxan CCT001909 (Fig. 4C) is reported to inhibit biosynthesis of nucleic acid in murine leukemia cells 26 while causing DNA cleavage at higher concentrations, and it was recently identified as an activator of p53-dependent transcription. 27 The 2-nitrothiophene 28 CCT070778 (Fig. 4C) belongs to a class of chemically reactive bacteriocides. 29 In contrast, CCT001643 (Fenticlor, a fungicide 30 ) and the dibromopyridine 31 CCT070795 (Fig. 4C) inhibited calciuminduced involucrin expression without affecting the clonogenic potential of keratinocytes (Fig. 4A, B) .
Screening for novel differentiation-promoting compounds
We next used the In-Cell Western assay to identify compounds that promoted involucrin expression in keratinocytes under low-calcium conditions. When applied at a concentration of 20 µM, 1 compound, CCT002080 (NCI 12155, [1, 3-bis (2-methyl-4-aminoquinoline-6-yl) urea], aminoquinuride 32 ), induced involucrin expression to the same extent as addition of 1.0 mM CaCl 2 (Fig. 5A) . The chemical structure of the compound is shown in Figure 5B . In addition to its use as an antiseptic, 32 CCT002080 has been reported to inhibit anthrax lethal factor metalloprotease, 33 vaccinia DNA topoisomerase, 34 and Kaposi's sarcoma-associated herpesvirus DNA synthesis. 35 The induction of differentiation by 20 µM CCT002080 was confirmed by flow cytometry of cells stained with anti-involucrin (SY5) or antibodies to a 2nd terminal differentiation marker, transglutaminase 1 (BC1; Fig. 5C ). In contrast, 5 µM CCT002080 did not stimulate differentiation (Fig. 5C) . Although the compound induced terminal differentiation at 20 µM, it did not stimulate apoptosis, as there was no increase in cells with a sub-G1 DNA content (M1 in Fig. 5D ). This is consistent with other reports that terminal differentiation and apoptosis are under the control of separate regulatory mechanisms in keratinocytes. 5, 36 In addition to inducing terminal differentiation, CCT002080 reduced the colony-forming ability of primary human keratinocytes in a concentration-dependent manner (Fig. 5E) . The growth-inhibitory effect of CCT002080 was at least partially selective for keratinocytes because it did not inhibit proliferation of J2-3T3 fibroblastic cells (Fig. 5F) .
CCT002080 induces expression of differentiation markers and apoptosis in a SCC cell line
A compound that stimulates keratinocyte terminal differentiation is of potential value as an anticancer agent if it can also promote differentiation of the oncogenically transformed keratinocytes in SCCs. This is because poorly differentiated SCCs have a worse prognosis than well-differentiated tumors. 37, 38 We therefore tested the effect of CCT002080 on SCC4 cells, a poorly differentiated cell line derived from a human tongue SCC. 15 One of the reasons for the failure of SCC4 cells to differentiate is that they are heterozygous for an activating mutation in the β1 integrin gene. 4 Whereas CCT002080 induced keratinocyte differentiation at 20 µM and not at 5 µM (Fig. 5C) , it stimulated differentiation of SCC4 at both concentrations (Fig. 6A) . The compound also inhibited SCC4 growth (Fig. 6B) . In addition, CCT002080 stimulated apoptosis. SCC4 cells cultured in serum-free KSFM medium had a sub-G1 population of 24% of total cells, and treatment with 20 µM CCT002080 increased the apoptotic population to 59% (M1 in Fig. 6C ).
DISCUSSION
We have shown that the In-Cell Western assay can be used to screen for differentiation-promoting or -inhibiting compounds in primary human keratinocytes. A similar approach, using different markers, has previously been used to screen for potential antipsoriatic compounds. 12, 13 Keratinocyte-based assays are also likely to be useful to screen for compounds that modulate keratinocyte cytokine production. 20 We have confirmed previous observations that certain agents promote (staurosporine) or inhibit (U0126) keratinocyte differentiation. [23] [24] [25] HDAC has been reported to regulate keratinocyte differentiation, 39 and it is thus of interest that 2 HDAC inhibitors, SAHA and SBHA, were verified as differentiation regulators in our screens. In addition, there was generally good agreement between the results based on expression of endogenous involucrin protein and those based on the activity of the involucrin promoter introduced by transient transfection.
Identification of agents that inhibit terminal differentiation is primarily of interest for the information that they provide about the differentiation process, rather than for obvious clinical benefit. One caveat with respect to the screen was that agents that appeared to block differentiation (including 10 µM staurosporine) may in fact be causing cell death. This necessitates a secondary screen for apoptosis and for inhibition of clonal growth. Because the number of hits in the primary screens was low, such additional screening does not pose any logistical problems. Two of the compounds we identified, CCT001643 and CCT070795, were selective inhibitors of differentiation by the additional criteria and will be of interest in exploring the link between cell cycle withdrawal and initiation of terminal differentiation. 5, 14 Of note was the compound CCT002080 (which has shown a number of other biological activities [32] [33] [34] [35] ) that we found promoted keratinocyte differentiation. This compound is particularly interesting because it had the same effect, and at lower doses, on SCC cells, although not affecting a fibroblastic cell line, J2-3T3. It may be significant that the compound triggered apoptosis in SCC4 cells but not primary keratinocytes because we have speculated that apoptosis acts as a fail-safe device to prevent proliferation of SCC cells that fail to respond to a terminal differentiation stimulus. 5, 36 It will clearly be of interest to uncover the targets of this compound in normal and tumorderived keratinocytes.
In conclusion, we have discovered novel modifiers of keratinocyte differentiation, which could have potential for the treatment of skin diseases with dysfunctions of the differentiation process. Although surgery for SCC can be curative, it is not always desirable because the lesions are sometimes distributed on exposed skin surfaces, such as the face or the back of the hands. The combination of surgery and differentiation induction may therefore be an effective way to treat SCC.
